Aurinia Pharmaceuticals Inc (NAS:AUPH)
$ 5.42 0.04 (0.74%) Market Cap: 775.16 Mil Enterprise Value: 538.07 Mil PE Ratio: 0 PB Ratio: 2.17 GF Score: 73/100

Q2 2020 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Aug 11, 2020 / 08:30PM GMT
Release Date Price: $14 (-2.51%)
Operator

Greetings, and welcome to the Aurinia Pharmaceuticals Second Quarter 2020 Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Dr. Glenn Schulman, Head of Investor Relations. Thank you. You may begin.

Glenn Schulman
Aurinia Pharmaceuticals Inc. - SVP of Corporate Communications & IR

Thank you, Jesse, and good afternoon, everyone. Welcome to Aurinia's second quarter 2020 conference call. Joining me on the call from the Aurinia team today are Mr. Peter Greenleaf, President and CEO; our Chief Commercial Officer, Mr. Max Colao; Mr. Joe Miller, our Chief Financial Officer; and Dr. Neil Solomons, Chief Medical Officer of Aurinia. This afternoon, we issued our press release and associated financial statement package, detailing the second quarter 2020 financial results, both of which are available on our website at www.auriniapharma.com and filed via 6-K with the SEC.

Before jumping

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot